成人脓毒症生物标志物管理推荐:范围综述与批判性评价
该范围综述检索2016年至2025年3月的MEDLINE、Guidelines International Network、泛美卫生组织、Trip Database和UpToDate,纳入至少检索一个文献来源并提供成人脓毒症生物标志物临床推荐(诊断和预后,包括治疗反应)的指导文件。共找到10份指导文件,仅一半(4/8)方法学可靠;共31条生物标志物推荐,其中24条(77.4%)关于单一生物标志物,乳酸(23条;74.2%)和降钙素原(8条;25.8%)最常被推荐;28条(90.3%)推荐聚焦预后。16条(51.6%)推荐为强推荐,13条(42.0%)为条件推荐。作者结论认为成人脓毒症指导文件方法学差,呼吁在特定预后场景中更谨慎使用生物标志物并联合标准临床评估,未来需提高指导文件方法学质量以生成更有效稳健的推荐。
要点
- 共纳入10份成人脓毒症指导文件,仅4/8(一半)在AGREE-II「严谨性」领域评分≥50%被判定为方法学可靠。
- 31条生物标志物推荐中24条(77.4%)针对单一生物标志物,乳酸最常被推荐(23条;74.2%),其次为降钙素原(8条;25.8%)。
- 28条(90.3%)推荐聚焦预后(含治疗反应),而非诊断。
- 16条(51.6%)推荐为强推荐,13条(42.0%)为条件推荐。
- 作者认为应更谨慎地在特定预后场景中使用生物标志物,并联合标准临床评估。
适用人群与场景
- 成人脓毒症患者(指导文件覆盖的诊断与预后管理场景)。
研究设计与关键结果
- 研究类型:范围综述与批判性评价,检索MEDLINE、Guidelines International Network、泛美卫生组织、Trip Database和UpToDate(2016年至2025年3月),纳入至少检索一个文献来源并提供成人脓毒症生物标志物临床推荐(诊断和预后,包括治疗反应)的指导文件。
- 共纳入10份指导文件,采用AGREE-II工具评估质量,仅4/8(一半)在「严谨性」领域评分≥50%被判定为方法学可靠。
- 共31条生物标志物推荐,24条(77.4%)关于单一生物标志物,乳酸(23条;74.2%)和降钙素原(8条;25.8%)最常被推荐;28条(90.3%)聚焦预后。
- 采用GRADE系统评估推荐强度:16条(51.6%)为强推荐,13条(42.0%)为条件推荐。
证据类型、等级与局限
- 证据类型:范围综述与批判性评价,采用AGREE-II工具评估指导文件质量,采用GRADE系统评估推荐强度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,应更谨慎地在特定预后场景中使用生物标志物,并联合标准临床评估。
- 作者认为,提高未来指导文件的方法学质量对于生成更有效和稳健的推荐以优化患者护理至关重要。
指南或共识出处
- BMJ Open发表的「成人脓毒症生物标志物管理推荐:范围综述与批判性评价」。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: A synthesis and appraisal of the recommendations for biomarkers in practice guidelines concerning sepsis is required to consolidate evidence-based practice. We generated an evidence gap map (EGM) on the use of biomarkers for managing adults with sepsis.
DESIGN: Scoping review.
DATA SOURCES: MEDLINE, Guidelines International Network, Pan American Health Organization, Trip Database and UpToDate were searched from 2016 to March 2025.
ELIGIBILITY CRITERIA: Guidance documents (GD) that searched at least one literature source and provided clinical recommendations for the use of biomarkers for the management (diagnosis and prognosis, including treatment response) of adults with sepsis.
DATA EXTRACTION AND SYNTHESIS: Two reviewers independently applied the eligibility criteria and extracted data. We used the AGREE-II (Appraisal of Guidelines for Research and Evaluation) tool to assess the GD quality. GDs that scored ≥50% on the AGREE-II 'Rigour of development' domain were considered robust. We also applied the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system to evaluate if the recommendations were strong or conditional.
RESULTS: We found 10 GDs, with only half (4/8) having a robust methodology. There were 31 recommendations concerning biomarkers. Among these, 24 (77.4%) recommendations were about single biomarkers, with lactate (23; 74.2%) and procalcitonin (8; 25.8%) most frequently recommended. Biomarker testing focused on prognosis in 28 (90.3%) recommendations. Overall, 16 (51.6%) recommendations were graded strong and 13 (42.0%) were conditional, which we displayed in an EGM.
CONCLUSIONS: The methodology of GDs concerning adult sepsis was poor. Our review calls for more prudent use of biomarkers in specific prognostic scenarios and in combination with standard clinical assessments. Enhancing the methodological quality of future GDs is essential to generate more valid and robust recommendations for optimising patient care.
参考来源
- Mateos-Haro M, Garcia-Santa-Vinuela A, Molano-Franco D, et al. Recommendations for the use of biomarkers for the management of adults with sepsis: a scoping review and critical appraisal. BMJ Open. 2025. PMID: 40623745. doi:10.1136/bmjopen-2024-090922
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。